Novel Rx

Dr. John Cush RheumNow
3 years 6 months ago
Factors Associated with Poor Vaccine Response in Rituximab: Dr. Yuzaiful Yusof (@Yuz6Yusof) discusses abstract #0437 presented at the #ACR21 annual meeting.
https://t.co/T0PFiZlbTa https://t.co/idj5T7j7ke


Richard Conway RichardPAConway
3 years 6 months ago
Comparative risks of skin SCC and BCC with different DMARDs. Abatacept appeared worst, HR 2.18, but may be residual confounding due to burden disease/comorbidities. Abstr#1942 #ACR21 @RheumNow https://t.co/UzOwuKKFmX


Janet Pope Janetbirdope
3 years 6 months ago
Who declines most with #scleroderma #ILD - early dcSSc, ⬆️CRP, ⬆️mRSS all w more ⤵️FVC. Results verified in SENSIS trial of SSc ILD where #nintedanib was superior to placebo abst#1846 #ACR21 @RheumNow https://t.co/eckUj0qwch


Robert B Chao, MD doctorRBC
3 years 6 months ago
Should we be measuring drug levels in pts taking infliximab?
⭐️Drug monitoring vs. standard dosing showed 73% sustained control vs. 55% (RA, PsA, SpA, UC, Crohn's, PsO)
#ACR21
Abs#1946
#ACRBest @RheumNow
https://t.co/sWMen50ljP https://t.co/F4Wpqis3id


Janet Pope Janetbirdope
3 years 6 months ago
OK is this a swan or a swan song? Graph looks like a swan 🦢 but message is NO #MACE differences in PsA on csDMARDs v #biologics #ACR21 abst#1833 @RheumNow https://t.co/TM91z5wiFY

Janet Pope Janetbirdope
3 years 6 months ago
So are we in an era of #monotherapy with bDMARDs in #PsA? Ustekinumab & Secukinumab not different w or without #MTX. Abst#L12 @RheumNow #ACR21 https://t.co/Zp5owTpLvm

Mike Putman EBRheum
3 years 6 months ago
Important late breaker @TerrierBen, DBRCT of RTX vs GC (FFS=0) or CYC (FFS>0) for EGPA
RTX not superior to CYC (64% RTX vs 60% CYC BVAS remission d180, p = 0.745); similar in subgroups
Feel like this lends support to (~surprising) ACR/VF recs for EGPA?
#ACR21 #ACRAmbassador https://t.co/gpsPtXF6pj


Eric Dein ericdeinmd
3 years 6 months ago
#ACR21 L19: TitAIN: Secukinumab for GCA
⭐️Phase 2 study with n=52
⭐️70% of SEC sustained remission at wk 28 vs 20% PBO, 59% at week 52 vs 8%
⬇️Cumulative prednisolone through wk 52 (2.8g v 3.4g)
- Looking forward to larger study
@Rheumnow
https://t.co/cuM9LcEr4u https://t.co/TmyS0kixFg


Eric Dein ericdeinmd
3 years 6 months ago
#ACR21 L21. REOVAS: RTX for EGPA
⭐️CYC traditionally preferred for 5-factor score>0
▶️Remission rates and relapse-free survival comparable bw RTX and conventional. RTX not superior for induction
▶️No diff in ANCA+/-, naive v relapse, FFS
https://t.co/cuM9LcEr4u @Rheumnow

Dr. Rachel Tate uptoTate
3 years 6 months ago
Racial disparities & Co-morbidities in PsA findings. Amongst important others, increased biologic use in Caucasians w/ PsA vs DMARDs in black PsA pts. View Abs 1780 for other relevant findings. #ACR21 #RheumNow #ACRbest @RheumNow https://t.co/0uKsa8i0bG https://t.co/R9YkxYqXws
